Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery
Award amount
$286,536Program and phase
STTR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- DISCOVERYBIOMED, INC.
- Proposal award date
- 2018-09-01
- Contract end date
- 2019-08-31
- UEI
- LR7QH452JJ31
- Solicitation number
- PA18-906
- Topic code
- NIDCD
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Broad Spectrum Bitter Taste Antagonists Discovery
- STING Inhibitor Discovery for Rare and Common Autoimmune Diseases
- Humanized Kidney Cellular Toxicity Platforms
- Humanized Kidney Cellular Toxicity Platforms
- Genotyped and Single Cyst-derived Human ADPKD Cell Platforms for Industry and Academia
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Cell type-specific gene therapy approach for TOMT-linked congenital hearing loss
- Real time speech enhancement/noise reduction for the hearing impaired
- Development of a Navigation-Based Insertion Tool for Trajectory Optimization during Cochlear Implantation
- Phonocath - An endovascular medical device to objectively evaluate Pulsatile Tinnitus
- Smartphone based custom-fit and low-cost hearing aids manufacturing system
Research funding history
19 SBIR/STTR records share this UEI (2008–2020). Reported award amounts total $11,512,428. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services